$0.73 $0.01 (1.9%)

08:00 PM EDT on 07/02/20

Acorda Therapeutics, Inc. (NASDAQ:ACOR)

CAPS Rating: 2 out of 5

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.

Current Price $0.73 Mkt Cap $35.2M
Open $0.00 P/E Ratio 0.00
Prev. Close $0.73 Div. (Yield) $0.00 (0.0%)
Daily Range $0.00 - $0.00 Volume 725,762
52-Wk Range $0.70 - $7.35 Avg. Daily Vol. 2,449,763

Caps

How do you think NASDAQ:ACOR will perform against the market?

Add Stock to CAPS Watchlist

All Players

190 Outperform
89 Underperform
 

All-Star Players

19 Outperform
19 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:ACOR Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

OKwarrior (22.36)
Submitted June 09, 2014

biotech w/ actual cash flow and no negatives on the EPS. Valuations are pretty high, but that is because of the hope for the big score on MS drugs.

Hogty (60.40)
Submitted September 01, 2009

Overvalued. If you want in on the future of CNS research and production invest in a broader, safer buy like STEM. They will benefit from the production and storage regardless of who comes up with the new tech. Short the fall. Not sure when or if I… More

NASDAQ:ACOR VS S&P 500 (SPY)

Fools bullish on NASDAQ:ACOR are also bullish on:

Fools bearish on NASDAQ:ACOR are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about ACOR.

Recs

0
Member Avatar Bigsef77 (69.45) Submitted: 2/21/2019 1:52:26 PM : Outperform Start Price: $29.30 NASDAQ:ACOR Score: -108.79

Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates
[Zacks]
Zacks Equity Research
,Zacks•February 15, 2019

Acorda Therapeutics, Inc. ACOR announced fourth-quarter 2018 earnings per share of 45 cents, significantly beating the Zacks Consensus Estimate of a loss of 60 cents. However, the figure declined from the year-ago earnings of 61 cents.

Acorda generated total revenues of $69.1 million in the fourth quarter, comprehensively outshining the Zacks Consensus Estimate of $41 million. However, sales tumbled a massive 63.3% year over year.

Shares of Acorda have plunged 38% in the past year, wider than the industry’s decline 18.4%.

Recs

0
Member Avatar benyboy (< 20) Submitted: 9/28/2014 10:44:57 PM : Outperform Start Price: $35.00 NASDAQ:ACOR Score: -156.83

Jim

Recs

1
Member Avatar OKwarrior (22.36) Submitted: 6/9/2014 1:33:24 AM : Outperform Start Price: $35.54 NASDAQ:ACOR Score: -157.55

biotech w/ actual cash flow and no negatives on the EPS. Valuations are pretty high, but that is because of the hope for the big score on MS drugs.

Leaderboard

Find the members with the highest scoring picks in ACOR.

Score Leader

SanDieguito

SanDieguito (93.91) Score: +388.85

The Score Leader is the player with the highest score across all their picks in ACOR.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
SanDieguito 93.91 3/31/2009 Underperform 3Y $20.11 -96.35% +292.50% +388.85 0 Comment
jmacn22 32.09 2/5/2009 Underperform 3Y $24.46 -97.00% +273.45% +370.45 1 Comment
anticitradeshort 28.73 4/20/2009 Underperform NS $18.42 -96.02% +268.32% +364.33 0 Comment
Nivaos < 20 8/17/2009 Underperform 1Y $23.27 -96.85% +216.95% +313.80 0 Comment
Hogty 60.40 9/1/2009 Underperform 3M $21.87 -96.64% +212.50% +309.14 2 Comments
BetapegAnalytics < 20 8/13/2009 Underperform 5Y $23.92 -96.93% +210.19% +307.12 0 Comment
BuyTheDip 40.04 10/2/2009 Underperform 3W $22.01 -96.67% +205.65% +302.32 0 Comment
dexxyru < 20 10/5/2009 Underperform 5Y $22.70 -96.77% +202.32% +299.08 0 Comment
Phoenix748 < 20 10/6/2008 Underperform NS $20.68 -96.45% +198.56% +295.01 0 Comment
lanceur 98.54 11/5/2009 Underperform 5Y $22.77 -96.78% +195.11% +291.88 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ACOR.